Ankylosing spondylitis

ADALIMUMAB, ETANERCEPT AND INFLIXIMAB

NICE Appraisal

TA143  Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis

DSU Reports

Ankylosing spondylitis: a comparison of cost effectiveness models (May 2007)

Comparisons of submitted models for the appraisal of etanercept, adalimumab and infliximab for ankylosing spondylitis (February 2007)

Related publications

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply
Rheumatology 2008; Vol 47 (10): 1590

A Wailoo, N Bansback, J Chilcott.Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
Rheumatology 2008;
Vol 47 (2): 119-120